Trial Profile
A Phase 1/2, Proof-of-Principle, Multi-Center, Open-Label, Single-Arm, Non-randomized Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine Consisting of Genetically Modified Allogeneic (Human) Tumor Cells for the Expression of IL-7, GM-CSF, CD80 and CD154, in Fixed Combination With a DNA-based Double Stem Loop Immunomodulator in Patients With Advanced Renal Cell Carcinoma (ASET Study).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs MGN 1601 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Proof of concept
- Acronyms ASET
- Sponsors Mologen
- 13 Nov 2018 Status changed from active, no longer recruiting to completed.
- 06 Nov 2018 This trial has been completed in Germany.
- 22 Mar 2017 Planned End Date changed from 1 Nov 2017 to 1 Aug 2018.